Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease

Julia J. Scialla

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose of review Fibroblast growth factor 23 (FGF23) regulates phosphate and vitamin D homeostasis and rises as kidney function declines. Animal studies have demonstrated direct and indirect effects of FGF23 that may promote heart disease. Herein, we review the recent epidemiologic literature evaluating the relationship between FGF23 and cardiovascular disease. Recent findings In observational prospective studies, higher FGF23 associates with a greater risk of incident cardiovascular disease including ischemic heart disease, stroke, heart failure, and atrial fibrillation. These studies establish a temporal sequence of events over long-term follow-up that suggest a possible role of FGF23 in cardiovascular disease pathogenesis. In most studies, risk is generally graded; however, in the largest study to date, higher FGF23 within the low-normal range was not associated with higher risk. In several recent studies higher FGF23 associated more strongly with the risk of congestive heart failure compared with atherosclerotic events, a finding consistent with surrogate endpoints and animal experiments. Currently, the utility of FGF23 as a predictive biomarker of cardiovascular risk is not established, and interventions to reduce FGF23 need to be studied to confirm its possible pathophysiologic role. Summary Higher FGF23 is associated with the subsequent development of cardiovascular disease, and perhaps most notably heart failure, in a growing number of studies. These findings bolster ongoing efforts to lower FGF23 using strategies to reduce phosphate intake and absorption.

Original languageEnglish (US)
Pages (from-to)260-267
Number of pages8
JournalCurrent Opinion in Nephrology and Hypertension
Volume24
Issue number3
DOIs
StatePublished - May 27 2015

Fingerprint

Cardiovascular Diseases
Heart Failure
fibroblast growth factor 23
Biomarkers
Phosphates
Vitamin D
Atrial Fibrillation
Observational Studies
Myocardial Ischemia
Heart Diseases
Reference Values
Homeostasis
Stroke
Prospective Studies
Kidney

Keywords

  • cardiovascular disease
  • chronic kidney disease
  • congestive heart failure
  • fibroblast growth factor 23
  • phosphate homeostasis

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease. / Scialla, Julia J.

In: Current Opinion in Nephrology and Hypertension, Vol. 24, No. 3, 27.05.2015, p. 260-267.

Research output: Contribution to journalArticle

@article{8ee6604e82654a2ebc2f28538b5bd86c,
title = "Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease",
abstract = "Purpose of review Fibroblast growth factor 23 (FGF23) regulates phosphate and vitamin D homeostasis and rises as kidney function declines. Animal studies have demonstrated direct and indirect effects of FGF23 that may promote heart disease. Herein, we review the recent epidemiologic literature evaluating the relationship between FGF23 and cardiovascular disease. Recent findings In observational prospective studies, higher FGF23 associates with a greater risk of incident cardiovascular disease including ischemic heart disease, stroke, heart failure, and atrial fibrillation. These studies establish a temporal sequence of events over long-term follow-up that suggest a possible role of FGF23 in cardiovascular disease pathogenesis. In most studies, risk is generally graded; however, in the largest study to date, higher FGF23 within the low-normal range was not associated with higher risk. In several recent studies higher FGF23 associated more strongly with the risk of congestive heart failure compared with atherosclerotic events, a finding consistent with surrogate endpoints and animal experiments. Currently, the utility of FGF23 as a predictive biomarker of cardiovascular risk is not established, and interventions to reduce FGF23 need to be studied to confirm its possible pathophysiologic role. Summary Higher FGF23 is associated with the subsequent development of cardiovascular disease, and perhaps most notably heart failure, in a growing number of studies. These findings bolster ongoing efforts to lower FGF23 using strategies to reduce phosphate intake and absorption.",
keywords = "cardiovascular disease, chronic kidney disease, congestive heart failure, fibroblast growth factor 23, phosphate homeostasis",
author = "Scialla, {Julia J.}",
year = "2015",
month = "5",
day = "27",
doi = "10.1097/MNH.0000000000000123",
language = "English (US)",
volume = "24",
pages = "260--267",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease

AU - Scialla, Julia J.

PY - 2015/5/27

Y1 - 2015/5/27

N2 - Purpose of review Fibroblast growth factor 23 (FGF23) regulates phosphate and vitamin D homeostasis and rises as kidney function declines. Animal studies have demonstrated direct and indirect effects of FGF23 that may promote heart disease. Herein, we review the recent epidemiologic literature evaluating the relationship between FGF23 and cardiovascular disease. Recent findings In observational prospective studies, higher FGF23 associates with a greater risk of incident cardiovascular disease including ischemic heart disease, stroke, heart failure, and atrial fibrillation. These studies establish a temporal sequence of events over long-term follow-up that suggest a possible role of FGF23 in cardiovascular disease pathogenesis. In most studies, risk is generally graded; however, in the largest study to date, higher FGF23 within the low-normal range was not associated with higher risk. In several recent studies higher FGF23 associated more strongly with the risk of congestive heart failure compared with atherosclerotic events, a finding consistent with surrogate endpoints and animal experiments. Currently, the utility of FGF23 as a predictive biomarker of cardiovascular risk is not established, and interventions to reduce FGF23 need to be studied to confirm its possible pathophysiologic role. Summary Higher FGF23 is associated with the subsequent development of cardiovascular disease, and perhaps most notably heart failure, in a growing number of studies. These findings bolster ongoing efforts to lower FGF23 using strategies to reduce phosphate intake and absorption.

AB - Purpose of review Fibroblast growth factor 23 (FGF23) regulates phosphate and vitamin D homeostasis and rises as kidney function declines. Animal studies have demonstrated direct and indirect effects of FGF23 that may promote heart disease. Herein, we review the recent epidemiologic literature evaluating the relationship between FGF23 and cardiovascular disease. Recent findings In observational prospective studies, higher FGF23 associates with a greater risk of incident cardiovascular disease including ischemic heart disease, stroke, heart failure, and atrial fibrillation. These studies establish a temporal sequence of events over long-term follow-up that suggest a possible role of FGF23 in cardiovascular disease pathogenesis. In most studies, risk is generally graded; however, in the largest study to date, higher FGF23 within the low-normal range was not associated with higher risk. In several recent studies higher FGF23 associated more strongly with the risk of congestive heart failure compared with atherosclerotic events, a finding consistent with surrogate endpoints and animal experiments. Currently, the utility of FGF23 as a predictive biomarker of cardiovascular risk is not established, and interventions to reduce FGF23 need to be studied to confirm its possible pathophysiologic role. Summary Higher FGF23 is associated with the subsequent development of cardiovascular disease, and perhaps most notably heart failure, in a growing number of studies. These findings bolster ongoing efforts to lower FGF23 using strategies to reduce phosphate intake and absorption.

KW - cardiovascular disease

KW - chronic kidney disease

KW - congestive heart failure

KW - fibroblast growth factor 23

KW - phosphate homeostasis

UR - http://www.scopus.com/inward/record.url?scp=84928492340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928492340&partnerID=8YFLogxK

U2 - 10.1097/MNH.0000000000000123

DO - 10.1097/MNH.0000000000000123

M3 - Article

VL - 24

SP - 260

EP - 267

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 3

ER -